Response rate to eltrombopag after 4 (R4), 12 (R12) and 24 (R24) weeks of treatment
| . | No. of patients . | ORR (%) . | 95% CI . | CR (%) . | 95% CI . | R (%) . | NR (%) . |
|---|---|---|---|---|---|---|---|
| R4 | |||||||
| Total evaluable | 18 | 78 | 58-97 | 50 | 43-57 | 28 | 22 |
| CLL/SLL | 14 | 79 | 50 | 29 | 21 | ||
| LPL/WM, cHL | 4 | 75 | 50 | 25 | 25 | ||
| R12 | |||||||
| Total evaluable* | 17 | 65 | 42-88 | 59 | 36-82 | 6 | 35 |
| CLL/SLL | 14 | 64 | 64 | 0 | 36 | ||
| LPL/WM, cHL | 3 | 66 | 33 | 33 | 34 | ||
| R24 | |||||||
| Total evaluable* | 17 | 59 | 36-82 | 30 | 8-52 | 29 | 41 |
| CLL/SLL | 14 | 64 | 28 | 36 | 36 | ||
| LPL/WM, cHL | 3 | 33 | 33 | 0 | 67 |
| . | No. of patients . | ORR (%) . | 95% CI . | CR (%) . | 95% CI . | R (%) . | NR (%) . |
|---|---|---|---|---|---|---|---|
| R4 | |||||||
| Total evaluable | 18 | 78 | 58-97 | 50 | 43-57 | 28 | 22 |
| CLL/SLL | 14 | 79 | 50 | 29 | 21 | ||
| LPL/WM, cHL | 4 | 75 | 50 | 25 | 25 | ||
| R12 | |||||||
| Total evaluable* | 17 | 65 | 42-88 | 59 | 36-82 | 6 | 35 |
| CLL/SLL | 14 | 64 | 64 | 0 | 36 | ||
| LPL/WM, cHL | 3 | 66 | 33 | 33 | 34 | ||
| R24 | |||||||
| Total evaluable* | 17 | 59 | 36-82 | 30 | 8-52 | 29 | 41 |
| CLL/SLL | 14 | 64 | 28 | 36 | 36 | ||
| LPL/WM, cHL | 3 | 33 | 33 | 0 | 67 |
LPDs were diagnosed according to World Health Organization 2008 criteria. For CR, platelet count was ≥100 × 109/L; for R, platelet count was ≥30 × 109/L and included doubling of basal count in the absence of bleeding and rescue therapy.
cHL, classic Hodgkin lymphoma; CI, confidence interval; LPL, lymphoplasmacytic lymphoma; NR, no response; ORR, overall response rate, includes CR and R; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.
One patient with LPL/WM (patient 9, Figure 1) was not evaluable for response at weeks 12 and 24 because he died at week 5 while being responsive to the study drug.